Clinical trial • Phase I • Neurology|Rare Disease
ALN-HTT02 for Huntington's disease
Phase I trial of ALN-HTT02 for Huntington's disease. 46 participants.
Overview
- Trial Therapeutic Area
- Neurology|Rare Disease
- Trial Disease
- Huntington's disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 10-10-2024
- First CTIS Authorization Date
- 23-12-2024
Trial design
Phase I trial across 7 sites in Germany.
- Target Sample Size
- 46
Eligibility
Recruits 46 Vulnerable population selected (isVulnerablePopulationSelected = true). No further information on consent or assent handling provided in the record..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected = true). No further information on consent or assent handling provided in the record.
Recruitment
- Planned Sample Size
- 46
- Recruitment Window Months
- 69
Geography
- Total Number Of Sites
- 7
- Total Number Of Participants
- 46
Germany
- Earliest CTIS Part Ii Submission Date
- 29-11-2024
- Latest Decision Or Authorization Date
- 19-03-2026
- Processing Time Days
- 475
- Number Of Sites
- 7
- Number Of Participants
- 20
Sites
- Site Name
- Technische Universitaet Dresden
- Department Name
- Klinik für Neurologie
- Principal Investigator Name
- Björn Falkenburger
- Principal Investigator Email
- bjoern.falkenburger@ukdd.de
- Contact Person Name
- Björn Falkenburger
- Contact Person Email
- bjoern.falkenburger@ukdd.de
- Site Name
- Kbo Isar-Amper-Klinikum Taufkirchen (Vils)
- Department Name
- -
- Principal Investigator Name
- Alzbeta Muehlbaeck
- Principal Investigator Email
- alzbeta.muehlbaeck@kbo.de
- Contact Person Name
- Alzbeta Muehlbaeck
- Contact Person Email
- alzbeta.muehlbaeck@kbo.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Klinik für Psychiatrie und Psychotherapie
- Principal Investigator Name
- Josef Priller
- Principal Investigator Email
- josef.priller@charite.de
- Contact Person Name
- Josef Priller
- Contact Person Email
- josef.priller@charite.de
- Site Name
- Katholisches Klinikum Bochum gGmbH
- Department Name
- -
- Principal Investigator Name
- Carsten Saft
- Principal Investigator Email
- carsten.saft@rub.de
- Contact Person Name
- Carsten Saft
- Contact Person Email
- carsten.saft@rub.de
- Site Name
- George-Huntington-Institut GmbH
- Department Name
- -
- Principal Investigator Name
- Ralf Reilmann
- Principal Investigator Email
- ralf.reilmann@ghi-muenster.de
- Contact Person Name
- Ralf Reilmann
- Contact Person Email
- ralf.reilmann@ghi-muenster.de
- Site Name
- Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
- Department Name
- -
- Principal Investigator Name
- Patrick Weydt
- Principal Investigator Email
- patrick.weydt@ukbonn.de
- Contact Person Name
- Patrick Weydt
- Contact Person Email
- patrick.weydt@ukbonn.de
- Site Name
- Universitaetsklinikum Ulm AöR
- Department Name
- Huntington Ambulanz
- Principal Investigator Name
- Katrin Lindenberg
- Principal Investigator Email
- katrin.lindenberg@uni-ulm.de
- Contact Person Name
- Katrin Lindenberg
- Contact Person Email
- katrin.lindenberg@uni-ulm.de
Sponsor
Primary sponsor
- Full Name
- Alnylam Pharmaceuticals Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- ALN-HTT02
Related trials
Other published trials that may interest you.